Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.
Yi Lin, MD, PhD, an assistant professor of oncology, associate professor of medicine, and a consultant in the Division of Hematology and Division of Experimental Pathology and Laboratory Medicine at Mayo Clinic, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel (ide-cel; bb2121) in multiple myeloma.
The first results from the CRB-401 study, which included 33 patients, were published in the New England Journal of Medicine in May 2019, says Lin. At the 2020 ASH Annual Meeting & Exposition, the results of the full 62-patient cohort were presented at a median follow-up of 14.7 months.
The overall patient cohort that received treatment was comprised of individuals who had high-risk features; approximately one-third of patients had high-risk cytogenetics. Additionally, 37% had extramedullary plasmacytomas and half required a systemic bridging therapy while their CAR T-cell therapy was being manufactured, explains Lin. On average, 45% of patients had received more than 6 prior lines of therapy. Moreover, the majority of patients either had triple-refractory disease or were refractory to their most recent line of therapy, Lin concludes.